First in Human Study for the Assessment of Safety and Initial Performance of the EAS1 System

Inclusion Criteria:

* Adult male and female subjects (age ≥18 years at the date of informed consent signature)
* Subject is capable and willing to provide an informed consent
* Subjects with a known diagnosis of lung cancer at cT1a-T1c, cN0 stages
* At least one pulmonary tumor (primary or metastasis) ≤ 30 mm in maximal diameter, as confirmed by the latest standard of care imaging (CT/MRI), performed preferably up to 30 days prior to screening
* Subjects who are scheduled or deemed eligible by a thoracic surgeon for lung tumor resection
* Subject is able and willing to comply with the study procedures and visits
* There is ≥ 5mm of nodule-free lung parenchyma between target nodule and pleura or fissure, as confirmed by the latest standard of care imaging (CT/MRI), performed preferably up to 30 days prior to screening
* ECOG 0-1
* Stable doses of concomitant medications for at least four (4) weeks prior to enrollment

Exclusion Criteria:

* An inability to provide informed consent
* Subjects with contraindication for tumor resection
* Subjects with life expectancy \<12 months
* Target nodule is abutting main stem bronchus, main pulmonary vasculature, esophagus and/or trachea
* Subjects with Forced Expiratory Volume (FEV1) \<50%
* Total Lung Capacity (TLC)\< 80% of expected for age
* Diffusing Capacity (DCO) \< 60% of expected
* Oxygen saturation in free air of \<88%, or requiring more than 2 l/min oxygen to achieve saturation of 92%
* PCO2 of ≥ 45mm/Hg
* Subjects in exacerbations group E (high risk; ≥2 exacerbations per year or ≥1 requiring hospitalization and any level of symptoms)
* Severe emphysema, Bullous Emphysema or chronic obstructive pulmonary disease (COPD) (GOLD III/IV)
* Active and/or prolonged lung or bronchi infection, required an antibiotic treatment up to 21 days prior to screening and for more than 10 days of treatment
* Known history or current evidence of a significant bronchiectasis
* Evidence of lung Bullae the occupies more than one third of the lung intended for ablation
* Previous surgery in the lung intended for ablation; thoracic major surgery at the side intended for ablation
* Anticoagulation treatment that cannot be discontinued prior to the ablation, or a bleeding diathesis or platelets \<100 )K/µl)
* Pregnant or breastfeeding female subjects or female subjects who plan pregnancy during participation in the study
* Highly hypoxemic patients, according to investigator's discretion
* Subjects with implanted metal or electronic thoracic devices objects (such as pacemaker) that cannot be removed prior to procedure
* Subjects with contraindication for bronchoscopy
* Participation in any other interventional clinical trial with medication, medical device and/or supplements within 30 days prior to informed consent signature
* Any subject who, at the discretion of the investigator, may be jeopardized by study participation